Lab services company Charles River Laboratories (NYSE: CRL) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 2.2% year on year to $982.7 million. Its non-GAAP profit of $3.09 per share was 4% above analysts’ consensus estimates.
Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).
Charles River Laboratories (CRL) Q3 2026 highlights:
- Revenue $982.7 million vs S&P analysts’ estimates of $960.5 million (2.2% year-on-year decline, 2.3% beat)
- Adjusted EPS $3.09 vs S&P analysts’ estimates of $2.97 (4% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $11.45 at the midpoint, a 1.3% increase
- Operating margin 20.6%, up from 13.3% in the same quarter last year
- Organic revenue rose 4.7% year on year (beat)
- Market capitalization $15.62 billion
StockStory’s take
Charles River Laboratories reported a 2.2% year-over-year decline in sales for the most recent quarter, and the market responded negatively despite the company exceeding Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s results to stronger organic growth in its Discovery and Safety Assessment (DSA) and manufacturing segments, while highlighting the benefit from operational changes such as automation in manufacturing and divestment of non-core businesses. CEO Birgit Girshick noted, “We were encouraged by the acceleration of our revenue growth rate in the third quarter, as we had anticipated, including solid mid-single-digit organic growth in the DSA segment and high single-digit organic growth in the manufacturing segment.”
Looking ahead, Charles River Laboratories raised its full-year adjusted earnings forecast, with management emphasizing progress in cost-savings initiatives and the expectation that recent proposal activity will support ongoing growth. Girshick described the company’s modernization efforts and automation upgrades as central to driving future operating margin improvement, stating, “The Create the Future transformation program is expected to generate over $300 million in cumulative savings over the next four years.” Management also highlighted that most of the near-term growth will be volume-driven, with price increases—especially in the DSA segment—not expected to materially benefit results until late next year.
Key insights from management’s remarks
Management connected the quarter’s performance to improved demand from biopharmaceutical and biotech clients, greater efficiency from automation, and progress in strategic partnerships. They also noted that recent divestitures clarified underlying segment trends.
-
Biopharma demand recovery: Management pointed to increased proposal activity and a net book-to-bill ratio above 1x for DSA, indicating renewed investment among both large pharmaceutical and smaller biotech clients in preclinical and IND-enabling studies.
-
Manufacturing automation impact: The implementation of a fully automated manufacturing suite for Endosafe endotoxin cartridge technology increased capacity by 14% and enhanced digital traceability, supporting both operational efficiency and quality control.
-
Segment margin expansion: Operating margins improved notably, driven by the divestiture of the lower-margin CDMO business and operating leverage in the DSA and manufacturing segments, particularly from lower non-human primate sourcing costs and higher study volumes.
-
Strategic partnerships: The company secured an expanded relationship with a top 10 biopharmaceutical client for safety assessment services, expected to transition work over the next 12-18 months and deepen client engagement.
-
Progress in alternative methods: Initiatives like the virtual control group (VCG) for regulatory studies and rapid cell banking using in vitro sequencing demonstrate Charles River's efforts to modernize drug testing while reducing reliance on animal studies and accelerating timelines.
Drivers of future performance
Charles River’s management expects near-term growth to be driven by higher study volumes and operational efficiencies, while pricing actions are not likely to contribute meaningfully until later next year.
-
Volume-led growth outlook: Management believes the current uptick in proposal and booking activity will result in sustained volume-driven growth, particularly in the DSA and manufacturing segments, as biopharma R&D investment rebounds and more drug programs enter the pipeline.
-
Cost and efficiency initiatives: The Create the Future transformation program, including automation and workflow digitization, is expected to deliver substantial operating margin improvements, with over $300 million in cumulative savings targeted by 2030.
-
Pricing recovery delayed: Executives indicated that while discounting in DSA proposals is being reduced, the impact on realized prices will not be seen until the second half of next year due to the lag between bookings and revenue recognition. This timing creates a headwind for near-term margin expansion from pricing alone.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will be watching (1) whether proposal and booking momentum in the DSA segment translates into sustained revenue growth, (2) evidence that cost savings from automation and workflow digitization are materializing in operating margins, and (3) the pace at which pricing improvements in DSA proposals begin to impact reported revenue. Additional focus will remain on client uptake of new technology-driven services and further expansion of key partnerships.
Charles River Laboratories currently trades at $326.99, down from $351.87 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
